Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT05583110 · TERMINATED

Trial details

NCT number: NCT05583110
Sponsor: Spanish Breast Cancer Research Group
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Metastatic Breast Cancer Locally Advanced HER2 Positive Breast Carcinoma

Start date: 2023-03-08
Primary completion: 2025-05-30
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.